MX390332B - Una composición farmacéutica que comprende febuxostat e inosina para usarse en el tratamiento de enfermedades en donde existe una deficiencia de atp intracelular. - Google Patents
Una composición farmacéutica que comprende febuxostat e inosina para usarse en el tratamiento de enfermedades en donde existe una deficiencia de atp intracelular.Info
- Publication number
- MX390332B MX390332B MX2018002263A MX2018002263A MX390332B MX 390332 B MX390332 B MX 390332B MX 2018002263 A MX2018002263 A MX 2018002263A MX 2018002263 A MX2018002263 A MX 2018002263A MX 390332 B MX390332 B MX 390332B
- Authority
- MX
- Mexico
- Prior art keywords
- inosine
- febuxostat
- increasing
- diseases
- treatment
- Prior art date
Links
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 title abstract 3
- 229930010555 Inosine Natural products 0.000 title abstract 3
- 229960003786 inosine Drugs 0.000 title abstract 3
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 title abstract 2
- 229960005101 febuxostat Drugs 0.000 title abstract 2
- 230000007812 deficiency Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000003834 intracellular effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000001965 increasing effect Effects 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 108010093894 Xanthine oxidase Proteins 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 abstract 1
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 abstract 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 abstract 1
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 abstract 1
- 102000005773 Xanthine dehydrogenase Human genes 0.000 abstract 1
- 108010091383 Xanthine dehydrogenase Proteins 0.000 abstract 1
- 102100033220 Xanthine oxidase Human genes 0.000 abstract 1
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 229940028843 inosinic acid Drugs 0.000 abstract 1
- 235000013902 inosinic acid Nutrition 0.000 abstract 1
- 239000004245 inosinic acid Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015166372 | 2015-08-26 | ||
| PCT/JP2016/074644 WO2017033963A1 (ja) | 2015-08-26 | 2016-08-24 | 細胞内ａｔｐ増強剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018002263A MX2018002263A (es) | 2018-03-23 |
| MX390332B true MX390332B (es) | 2025-03-20 |
Family
ID=58100417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018002263A MX390332B (es) | 2015-08-26 | 2016-08-24 | Una composición farmacéutica que comprende febuxostat e inosina para usarse en el tratamiento de enfermedades en donde existe una deficiencia de atp intracelular. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10682372B2 (enExample) |
| EP (1) | EP3342414B1 (enExample) |
| JP (2) | JP6153281B1 (enExample) |
| KR (1) | KR102600879B1 (enExample) |
| CN (1) | CN107921054B (enExample) |
| BR (1) | BR112018002648B1 (enExample) |
| CA (1) | CA2995052C (enExample) |
| MX (1) | MX390332B (enExample) |
| RU (1) | RU2728722C2 (enExample) |
| WO (1) | WO2017033963A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3054963B1 (fr) * | 2016-08-10 | 2018-09-14 | Assistance Publique-Hopitaux De Paris (Ap-Hp) | Utilisation d'un inhibiteur de la synthese de novo des purines, dans le traitement du deficit en adenylosuccinate lyase |
| JP6937134B2 (ja) | 2016-11-21 | 2021-09-22 | 株式会社スタージェン | 細胞内ａｔｐ増強剤 |
| WO2018092911A1 (ja) * | 2016-11-21 | 2018-05-24 | 株式会社スタージェン | 細胞内ａｔｐ増強剤 |
| WO2020149218A1 (ja) * | 2019-01-18 | 2020-07-23 | 学校法人東京女子医科大学 | 老化防止剤または寿命延長剤 |
| WO2020174492A1 (en) | 2019-02-25 | 2020-09-03 | Celagenex Research (India) Pvt. Ltd. | Synergistic bioactive compositions for enhancing cellular energy |
| JP7333942B2 (ja) | 2019-06-07 | 2023-08-28 | 株式会社スタージェン | 神経変性疾患に対するａｔｐ増強療法の効果を予測する方法 |
| CN110441457A (zh) * | 2019-08-02 | 2019-11-12 | 深圳市绿航星际太空科技研究院 | 一种检测尿液中同型半胱氨酸的方法 |
| CA3201273A1 (en) | 2020-12-08 | 2022-06-16 | Miki Hiraoka | Intracellular atp enhancer |
| JPWO2023135827A1 (enExample) * | 2022-01-13 | 2023-07-20 | ||
| CN116763751A (zh) * | 2023-07-25 | 2023-09-19 | 华中药业股份有限公司 | 一种肌苷片及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6440455B1 (en) | 1997-09-02 | 2002-08-27 | Children's Medical Center Corporation | Methods for modulating the axonal outgrowth of central nervous system neurons |
| CA2658342A1 (en) | 2006-07-19 | 2008-01-24 | Nippon Medical School Foundation | Therapeutic agent for amyotrophic lateral sclerosis |
| US20090292021A1 (en) * | 2006-08-02 | 2009-11-26 | Inserm (Institut National De La Sante Et De La Rec | Anticonvulsive pharmaceutical compositions |
| CN103058944B (zh) * | 2007-11-27 | 2015-08-05 | 亚德生化公司 | 调节血液尿酸水平的化合物 |
| WO2011022757A1 (en) * | 2009-08-24 | 2011-03-03 | Queensland University Of Technology | Purine-targeted diagnosis and therapy of wounds |
| CN102106896B (zh) * | 2009-12-23 | 2012-05-30 | 昆明贝叶傣医药研究所 | 中药材土千年健在制药中的新应用 |
| EP2598494B1 (en) | 2010-07-30 | 2014-11-26 | Ranbaxy Laboratories Limited | Improved process for the preparation of febuxostat |
| CA2813555C (en) * | 2010-10-15 | 2014-11-25 | Ardea Biosciences, Inc. | Methods for treating hyperuricemia and related diseases |
| WO2012122532A2 (en) * | 2011-03-09 | 2012-09-13 | Biocryst Pharmaceuticals, Inc. | Compositions and methods for treatment of hyperuricemia |
| CN102994537A (zh) * | 2012-11-21 | 2013-03-27 | 广东肇庆星湖生物科技股份有限公司 | 一种嘌呤核苷磷酸化酶基因敲除的大肠杆菌Ecoli-SL26的构建方法 |
-
2016
- 2016-08-24 RU RU2018110363A patent/RU2728722C2/ru active
- 2016-08-24 US US15/754,842 patent/US10682372B2/en active Active
- 2016-08-24 BR BR112018002648-4A patent/BR112018002648B1/pt active IP Right Grant
- 2016-08-24 EP EP16839310.6A patent/EP3342414B1/en active Active
- 2016-08-24 WO PCT/JP2016/074644 patent/WO2017033963A1/ja not_active Ceased
- 2016-08-24 CA CA2995052A patent/CA2995052C/en active Active
- 2016-08-24 KR KR1020187007813A patent/KR102600879B1/ko active Active
- 2016-08-24 JP JP2016572842A patent/JP6153281B1/ja active Active
- 2016-08-24 MX MX2018002263A patent/MX390332B/es unknown
- 2016-08-24 CN CN201680049519.6A patent/CN107921054B/zh active Active
-
2017
- 2017-05-29 JP JP2017105857A patent/JP2017141308A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2995052A1 (en) | 2017-03-02 |
| KR102600879B1 (ko) | 2023-11-09 |
| CA2995052C (en) | 2023-08-22 |
| MX2018002263A (es) | 2018-03-23 |
| CN107921054B (zh) | 2020-12-04 |
| RU2728722C2 (ru) | 2020-07-30 |
| RU2018110363A (ru) | 2019-09-26 |
| JP2017141308A (ja) | 2017-08-17 |
| JP6153281B1 (ja) | 2017-06-28 |
| BR112018002648B1 (pt) | 2024-01-09 |
| CN107921054A (zh) | 2018-04-17 |
| HK1246165A1 (zh) | 2018-09-07 |
| JPWO2017033963A1 (ja) | 2017-08-24 |
| BR112018002648A2 (enExample) | 2018-10-02 |
| WO2017033963A1 (ja) | 2017-03-02 |
| US20180243326A1 (en) | 2018-08-30 |
| EP3342414A4 (en) | 2019-04-17 |
| EP3342414A1 (en) | 2018-07-04 |
| US10682372B2 (en) | 2020-06-16 |
| RU2018110363A3 (enExample) | 2020-01-29 |
| KR20180039164A (ko) | 2018-04-17 |
| EP3342414B1 (en) | 2022-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390332B (es) | Una composición farmacéutica que comprende febuxostat e inosina para usarse en el tratamiento de enfermedades en donde existe una deficiencia de atp intracelular. | |
| CY1124855T1 (el) | 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες | |
| IL268850A (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| CL2015003442A1 (es) | Derivados heterociclicos | |
| MX2016000307A (es) | Farmaco para el tratamiento de la esteatosis hepatica no alcoholica. | |
| MX2020010484A (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk. | |
| BRPI1011838B8 (pt) | compostos de carboxamida heterocíclica de diamino, seu uso, composição farmacêutica que os compreende e inibidor contra a atividade de cinase de proteína de fusão eml4-alk | |
| CL2017001488A1 (es) | Benzamidas sustituidas con 1,3–tiazol–2–ilo | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| CR20170411A (es) | Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina | |
| CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
| MX2020011100A (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar. | |
| BR112017010439A2 (pt) | composto, composição farmacêutica, combinação farmacêutica, kit, métodos para controle de uma doença fúngica em uma planta e para prevenção ou tratamento de doença fúngica em um indivíduo, e, uso de um composto | |
| EP3359159A4 (en) | PHARMACEUTICAL SALTS, PHYSICAL FORMS AND COMPOSITIONS OF PYRROLOPYRIMIDINE KINASE INHIBITORS AND METHOD FOR THE PRODUCTION THEREOF | |
| MX391489B (es) | Inhibidores heterociclicos de mct4. | |
| CL2018002807A1 (es) | Métodos de tratamiento de cánceres pediátricos. | |
| BR112018015718A2 (pt) | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) | |
| CL2017001479A1 (es) | Combinación farmacéutica que comprende un agonista selectivo del receptor s1p1 | |
| MX381735B (es) | Formulación sólida oral que contiene irinotecán y método de preparación de la misma. | |
| MX383254B (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
| MX2019001850A (es) | Formulaciones para administracion oral de principios activos. | |
| EA201791696A1 (ru) | Композиция для лечения веноокклюзионной болезни печени | |
| MX2018008307A (es) | Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk). | |
| EA201991570A1 (ru) | Амидные соединения и их применение |